275 related articles for article (PubMed ID: 33182650)
21. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
22. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
23. Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.
Liu Y; Cao M; Cai Y; Li X; Zhao C; Cui R
Front Cell Dev Biol; 2020; 8():95. PubMed ID: 32154250
[TBL] [Abstract][Full Text] [Related]
24. Prolonged circulation and increased tumor accumulation of liposomal vincristine in a mouse model of rhabdomyosarcoma.
Roveri M; Pfohl A; Jaaks P; Alijaj N; Leroux JC; Luciani P; Bernasconi M
Nanomedicine (Lond); 2017 May; 12(10):1135-1151. PubMed ID: 28447920
[TBL] [Abstract][Full Text] [Related]
25. Generation and characterization of a panel of monoclonal antibodies specific for human fibroblast growth factor receptor 4 (FGFR4).
Chen C; Patel S; Corisdeo S; Liu X; Micolochick H; Xue J; Yang Q; Lei Y; Wang B; Soltis D
Hybridoma (Larchmt); 2005 Jun; 24(3):152-9. PubMed ID: 15943563
[TBL] [Abstract][Full Text] [Related]
26. [Rhabdomyosarcoma lysis by T cells expressing a human autoantibody based chimeric receptor targeting the fetal acetylcholine receptors].
Gattenlöhner S
Verh Dtsch Ges Pathol; 2006; 90():264-76. PubMed ID: 17867605
[TBL] [Abstract][Full Text] [Related]
27. Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage.
Yu SJ; Zheng L; Ladanyi M; Asa SL; Ezzat S
Clin Cancer Res; 2004 Oct; 10(19):6750-8. PubMed ID: 15475466
[TBL] [Abstract][Full Text] [Related]
28. Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy.
Chen C; Sun Z; Wang Z; Shin S; Berrios A; Mellors JW; Dimitrov DS; Li W
Antibodies (Basel); 2024 May; 13(2):. PubMed ID: 38804307
[TBL] [Abstract][Full Text] [Related]
29. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies.
Wu C; Chen X; Chen D; Xia Q; Liu Z; Li F; Yan Y; Cai Y
Int J Biol Macromol; 2019 Aug; 135():294-302. PubMed ID: 31128178
[TBL] [Abstract][Full Text] [Related]
30. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
[TBL] [Abstract][Full Text] [Related]
32. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
[TBL] [Abstract][Full Text] [Related]
33. Ricin detection using phage displayed single domain antibodies.
Goldman ER; Liu JL; Bernstein RD; Swain MD; Mitchell SQ; Anderson GP
Sensors (Basel); 2009; 9(1):542-55. PubMed ID: 22389616
[TBL] [Abstract][Full Text] [Related]
34. Single-domain antibodies as promising experimental tools in imaging and isolation of porcine epidemic diarrhea virus.
Yang S; Li L; Yin S; Shang Y; Khan MUZ; He X; Yuan L; Gao X; Liu X; Cai J
Appl Microbiol Biotechnol; 2018 Oct; 102(20):8931-8942. PubMed ID: 30143837
[TBL] [Abstract][Full Text] [Related]
35. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
[TBL] [Abstract][Full Text] [Related]
36. Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent.
Broos K; Lecocq Q; Xavier C; Bridoux J; Nguyen TT; Corthals J; Schoonooghe S; Lion E; Raes G; Keyaerts M; Devoogdt N; Breckpot K
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234464
[TBL] [Abstract][Full Text] [Related]
37. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
38. Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma.
Repana D; Ross P
Diseases; 2015 Oct; 3(4):294-305. PubMed ID: 28943626
[TBL] [Abstract][Full Text] [Related]
39. Alteration in the serum concentrations of FGF19, FGFR4 and βKlotho in patients with thyroid cancer.
Motylewska E; Stępień T; Borkowska M; Kuzdak K; Siejka A; Komorowski J; Stępień H; Ławnicka H
Cytokine; 2018 May; 105():32-36. PubMed ID: 29438906
[TBL] [Abstract][Full Text] [Related]
40. Amplification of immunoassays using phage-displayed single domain antibodies.
Goldman ER; Anderson GP; Bernstein RD; Swain MD
J Immunol Methods; 2010 Jan; 352(1-2):182-5. PubMed ID: 19895814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
